Gerris J, Jacquemyn Y, Desmedt E, Delbeke L, Buytaert P
Department of Obstetrics and Gynaecology, University Hospital, Antwerp, Belgium.
Hum Reprod. 1989 Nov;4(8):937-40. doi: 10.1093/oxfordjournals.humrep.a137016.
New methods of ovulation induction have been discovered and perfected in recent years. Among others, gonadotrophin-releasing hormone (GnRH) agonists are being used increasingly in the treatment of ovulatory infertility. In a prospective study, 24 women undergoing artificial insemination with donor sperm (AID) and facing failure of treatment because of ovulation disorders, were treated with human menopausal gonadotrophin/human chorionic gonadotrophin (HMG/HCG) superovulation with or without pituitary densensitization using a superactive luteinizing hormone-releasing hormone (LHRH) agonist, buserelin (BUS), Suprefact (Hoechst, Frankfurt a/Main, FRG). In 86 cycles stimulated with HMG/HCG no pregnancy occurred, whereas 12 pregnancies occurred in the same group of patients after a total of 43 BUS/HMG/HCG stimulation cycles. Superactive LHRH agonists have a definite place in the treatment of AID patients presenting with refractory ovulation disorders and/or luteal insufficiency.
近年来，已发现并完善了新的促排卵方法。其中，促性腺激素释放激素（GnRH）激动剂在排卵障碍性不孕症的治疗中应用越来越广泛。在一项前瞻性研究中，24名因排卵障碍而接受供精人工授精（AID）且治疗失败的女性，接受了人绝经期促性腺激素/人绒毛膜促性腺激素（HMG/HCG）超促排卵治疗，使用超活性促黄体生成素释放激素（LHRH）激动剂布舍瑞林（BUS）、Suprefact（德国赫斯特公司，美因河畔法兰克福）进行垂体脱敏或不进行垂体脱敏。在86个接受HMG/HCG刺激的周期中未发生妊娠，而在同一组患者中，经过总共43个BUS/HMG/HCG刺激周期后有12例妊娠。超活性LHRH激动剂在治疗难治性排卵障碍和/或黄体功能不全的AID患者中具有明确的地位。
